- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
LabCorp total assets 2013-2018
LabCorp total assets 2013-2018
Total assets of Laboratory Corporation of America Holdings from 2013 to 2018 (in million U.S. dollars)
This statistic describes the total assets of contract researcher Laboratory Corporation of America Holdings (LabCorp) from 2013 to 2018. In 2018, total assets of LabCorp were about 16.2 billion U.S. dollars.
Total assets of Laboratory Corporation of America Holdings from 2013 to 2018 (in million U.S. dollars)
Loading statistic...
| Total assets in million U.S. dollars | |
|---|---|
| 2018 | 16,185.3 |
| 2017 | 16,673 |
| 2016 | 14,334.8 |
| 2015 | 14,104.7 |
| 2014 | 7,262.8 |
| 2013 | 6,939.8 |
| Total assets in million U.S. dollars | |
|---|---|
| 2018 | 16,185.3 |
| 2017 | 16,673 |
| 2016 | 14,334.8 |
| 2015 | 14,104.7 |
| 2014 | 7,262.8 |
| 2013 | 6,939.8 |
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
This statistic describes the total assets of contract researcher Laboratory Corporation of America Holdings (LabCorp) from 2013 to 2018. In 2018, total assets of LabCorp were about 16.2 billion U.S. dollars.
Show more- Show sources information
- Show publisher information
- Release date
- February 2019
- Region
- North America
- Survey time period
- 2013 to 2018
Source
- Show sources information
- Show publisher information
- Release date
- February 2019
More information
- Region
- North America
- Survey time period
- 2013 to 2018
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Clinical trials"
- R&D overview
The most important statistics
- Total global spending on pharmaceutical research and development from 2010 to 2024 (in billion U.S. dollars)Total global pharmaceutical R&D spending 2010-2024
- Percentage of spending on research and development of total revenue from 2012 to 2016, by industrial sector*Industry sectors - expenditure on research and development 2012-2016
- Selected top pharmaceutical R&D projects based on net present value (NPV) as of May 2018 (in million U.S. dollars)Top pharmaceutical R&D projects based on net present value May 2018
- Research and development expenditure of total U.S. pharmaceutical industry from 1995 to 2017 (in billion U.S. dollars)*Research and development expenditure: U.S. pharmaceutical industry 1995-2017
- Pharmaceutical research and development spending in selected European countries in 2016 (in million euros)Research and development in European pharmaceutical industry by country 2016
- Total clinical research funding by the National Institutes for Health (NIH) from FY 2013 to FY 2019 (in million U.S. dollars)Total clinical research funding by National Institutes for Health 2013-2019
- Top R&D companies
The most important statistics
- Global top 10 pharmaceutical companies based on projected R&D spending in 2024 (in billion U.S. dollars)Global top pharmaceutical companies based on R&D spending 2024
- World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2017/2018*Top 50 global pharmaceutical and biotech companies by R&D intensity in 2017/2018
- World's top 50 pharmaceutical and biotechnology companies based on R&D spending growth in 2017/2018Top pharmaceutical companies in R&D spending growth 2017-2018
- Number of patients who took part in clinical trials for pharmaceutical company Roche from 2009 to 2017*Roche: participation of patients in clinical trials 2009-2017
- Top global contract research organizations (CROs) based on 2017 revenue (in million U.S. dollars)Leading global contract research organizations based on revenue 2017
- Clinical studies
The most important statistics
- Complexity of clinical trials compared in 2001-2005 and 2011-2015Comparison between the complexity of clinical trials 2001-2015
- Increase in clinical trials' complexity between 2001-2005 and 2011-2015Increase in clinical trials' complexity 2001-2015
- Number of registered clinical studies worldwide by location as of August 2018Number of registered clinical studies by location worldwide 2018
- Percentage of registered clinical studies worldwide by location as of August 2018Percent of registered clinical studies worldwide by location 2018
- Percentage of registered recruiting clinical studies worldwide by location as of August 2018Share of recruiting clinical studies worldwide by location 2018
- Total number of registered clinical studies worldwide since 2000 (as of August 2018)*Total number of registered clinical studies worldwide since 2000
- Total number of registered clinical studies with posted results worldwide since 2009 (as of August 2018)*Total number of registered clinical studies with posted results worldwide 2009-2018
- Participation
The most important statistics
- Percentage of population enrolled in clinical trials in selected countries worldwide as of 2016Clinical trial enrollment by select country and region 2016
- Top 20 countries by number of clinical trial participants in 2015-2016Top clinical trial participant countries 2015-2016, by number
- Top 20 clinical trial participant countries worldwide in 2015-2016, by share of participants (in percentage)Top clinical trial participant countries worldwide 2015-16, by share
- Number of clinical trial participants in the U.S. and rest of the world in 2016, by therapeutic areaClinical trial participants U.S. vs. rest of world by therapy area 2016
- Gender share of clinical trial participants worldwide in 2015-2016, by geographic locationClinical trial participants gender share worldwide 2015-16, by geographic location
- Ethnicity share of clinical trial participants worldwide in 2015-2016, by geographic location (in percentage)Clinical trial participants ethnicity share worldwide 2015-16, by geographic location
- Costs and market
The most important statistics
- Cost of developing a drug in the U.S. from the 1970s until today (in million U.S. dollars)*Pharmaceuticals: cost of drug development in the U.S. since 1975
- Total R&D costs for selected cancer drugs on the market as of 2017 (in million U.S. dollars)Total R&D costs of select cancer drugs 2017
- Market share of clinical trials worldwide by segment as of 2016Market share of clinical trials worldwide by segment
- Clinical contract research organization (CRO) market worldwide from 2011 to 2020 (in billion U.S. dollars)Clinical CRO market size worldwide 2011-2020
- Size of the U.S. market for healthcare contract research outsourcing (CRO) from 2016 to 2022, by type (in million U.S. dollars)Size of U.S. healthcare CRO market 2016-2022 by type
- Size of the total U.S. clinical trial supplies market from 2016 to 2025 (in million U.S. dollars)Size of total U.S. clinical trial supplies market 2016-2025
- Success rates
The most important statistics
- Probability of success for drugs in the U.S. in different development phases between 2006 and 2015U.S. drug development phase success rates 2006-2015
- Probability of Phase II success for new drugs in select disease areas in the U.S. between 2006 and 2015U.S. drug development Phase II success rates 2006-2015, by disease area
- The probability of Phase III success for new drugs in select disease areas in the U.S. between 2006 and 2015U.S. drug development Phase III success rates from 2006 to 2015, by disease area
- Probability of success for oncology vs non-oncology drugs in the U.S. in the different development phases from 2006 to 2015U.S. development Phase success rates for oncology and non oncology drugs 2006-2015
- Probability of success for new drugs in the U.S. by development phase between 2006 and 2015, by drug classification U.S. drug development Phase success rates, by drug classification 2006-2015
- Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015U.S. development phase success rates for drugs with and without biomarkers 2006-2015
- Approvals, launches, setbacks
The most important statistics
- Number of new chemical or biological entities developed between 1992 and 2017, by region of originPharmaceutical industry - number of new substances 1992-2017
- Total number of novel drugs approved by CDER from 2008 to 2018Number of novel drugs approved annually by CDER 2008-2018
- Percentage of drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) in 2018 that met select key measurementsKey measurements of U.S. CDER drug approvals in 2018
- Number of first premarket approvals (PMA/HDE) granted by the FDA for medtech products from 2005 to 2018FDA first premarket approvals for medtech products granted 2005-2018
- Top biotech and pharma product launches in 2018 and revenue forecast for 2022 (in million U.S. dollars)Projection of top 2018 pharma and biotech launches by revenue 2022
- Number of unsuccessful Alzheimer’s drugs in development in the U.S. from 1998 to 2017Number of unsuccessful Alzheimer’s drugs in development in the U.S. 1998-2017
- Unsuccessful attempts and new drugs for select cancer types between 1998 and 2014Unsuccessful attempts and new drugs for cancer types 1998-2014
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- LabCorp operating income 2013-2018
- LabCorp basic earnings per common share 2013-2018
- LabCorp SG&A expenses 2016-2018
- LabCorp revenues from 2013 to 2018
- LabCorp net earnings 2013-2018
- LabCorp net revenues 2016-2018, by operation
- LabCorp SG&A expenses as percentage of revenues 2016-2018
- LabCorp number of employees 2014-2018
- Total assets of Syneos Health 2013-2018
- IQVIA total assets 2013-2018
- Genomma Lab: total assets 2013-2018
- Total assets of Bausch Health 2012-2018
- Intuitive Surgical: total assets 2013-2017
- Covidien's total assets 2007-2014
- Italy: total assets of selected innovative startups in Milan 2014-2016
- Danaher - total assets 2013-2018
- Terumo total assets FY 2012-2017
- NuVasive total assets 2012-2018
- Total investment fund financial asset ownership in the Euro area 2005-2015
- Operating income of the Spanish media group Vocento 2013-2018
Statistics on "Clinical trials"
- Total global spending on pharmaceutical research and development from 2010 to 2024 (in billion U.S. dollars)
- Percentage of spending on research and development of total revenue from 2012 to 2016, by industrial sector*
- Selected top pharmaceutical R&D projects based on net present value (NPV) as of May 2018 (in million U.S. dollars)
- Research and development expenditure of total U.S. pharmaceutical industry from 1995 to 2017 (in billion U.S. dollars)*
- Pharmaceutical research and development spending in selected European countries in 2016 (in million euros)
- Total clinical research funding by the National Institutes for Health (NIH) from FY 2013 to FY 2019 (in million U.S. dollars)
- Global top 10 pharmaceutical companies based on projected R&D spending in 2024 (in billion U.S. dollars)
- World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2017/2018*
- World's top 50 pharmaceutical and biotechnology companies based on R&D spending growth in 2017/2018
- Number of patients who took part in clinical trials for pharmaceutical company Roche from 2009 to 2017*
- Top global contract research organizations (CROs) based on 2017 revenue (in million U.S. dollars)
- Complexity of clinical trials compared in 2001-2005 and 2011-2015
- Increase in clinical trials' complexity between 2001-2005 and 2011-2015
- Number of registered clinical studies worldwide by location as of August 2018
- Percentage of registered clinical studies worldwide by location as of August 2018
- Percentage of registered recruiting clinical studies worldwide by location as of August 2018
- Total number of registered clinical studies worldwide since 2000 (as of August 2018)*
- Total number of registered clinical studies with posted results worldwide since 2009 (as of August 2018)*
- Percentage of population enrolled in clinical trials in selected countries worldwide as of 2016
- Top 20 countries by number of clinical trial participants in 2015-2016
- Top 20 clinical trial participant countries worldwide in 2015-2016, by share of participants (in percentage)
- Number of clinical trial participants in the U.S. and rest of the world in 2016, by therapeutic area
- Gender share of clinical trial participants worldwide in 2015-2016, by geographic location
- Ethnicity share of clinical trial participants worldwide in 2015-2016, by geographic location (in percentage)
- Cost of developing a drug in the U.S. from the 1970s until today (in million U.S. dollars)*
- Total R&D costs for selected cancer drugs on the market as of 2017 (in million U.S. dollars)
- Market share of clinical trials worldwide by segment as of 2016
- Clinical contract research organization (CRO) market worldwide from 2011 to 2020 (in billion U.S. dollars)
- Size of the U.S. market for healthcare contract research outsourcing (CRO) from 2016 to 2022, by type (in million U.S. dollars)
- Size of the total U.S. clinical trial supplies market from 2016 to 2025 (in million U.S. dollars)
- Probability of success for drugs in the U.S. in different development phases between 2006 and 2015
- Probability of Phase II success for new drugs in select disease areas in the U.S. between 2006 and 2015
- The probability of Phase III success for new drugs in select disease areas in the U.S. between 2006 and 2015
- Probability of success for oncology vs non-oncology drugs in the U.S. in the different development phases from 2006 to 2015
- Probability of success for new drugs in the U.S. by development phase between 2006 and 2015, by drug classification
- Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015
- Number of new chemical or biological entities developed between 1992 and 2017, by region of origin
- Total number of novel drugs approved by CDER from 2008 to 2018
- Percentage of drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) in 2018 that met select key measurements
- Number of first premarket approvals (PMA/HDE) granted by the FDA for medtech products from 2005 to 2018
- Top biotech and pharma product launches in 2018 and revenue forecast for 2022 (in million U.S. dollars)
- Number of unsuccessful Alzheimer’s drugs in development in the U.S. from 1998 to 2017
- Unsuccessful attempts and new drugs for select cancer types between 1998 and 2014
- Operating income of Laboratory Corporation of America from 2013 to 2018 (in million U.S. dollars)
- Earnings per share of Laboratory Corporation of America stocks from 2013 to 2018 (in U.S. dollars)*
- Selling, general and administrative expenses of Laboratory Corporation of America from 2016 to 2018 (in million U.S. dollars)
- Revenue of Laboratory Corporation of America from 2013 to 2018 (in million U.S. dollars)
- Net earnings of Laboratory Corporation of America Holdings from 2013 to 2018 (in million U.S. dollars)
- Net revenues of Laboratory Corporation of America Holdings from 2016 to 2018, by operation (in million U.S. dollars)
- Selling, general and administrative expenses as a share of revenues of Laboratory Corporation of America from 2016 to 2018
- Number of Laboratory Corporation of America's employees from 2014 to 2018*
- Syneos Health's total assets from 2013 to 2018 (in million U.S. dollars)
- Total assets of IQVIA from 2013 to 2018 (in million U.S. dollars)
- Total assets of Genomma Lab from 2013 to 2018 (in billion Mexican pesos)
- Total assets of Bausch Health Companies from 2012 to 2018 (in million U.S. dollars)
- Intuitive Surgical's total assets from FY 2013 to FY 2017 (in million U.S. dollars)
- Covidien's total assets from 2007 to 2014 (in million U.S. dollars)
- Total assets of selected innovative startups in Milan, Italy from 2014 to 2016 (in 1,000 euros)
- Danaher Corporation's total assets from FY 2013 to FY 2018 (in million U.S. dollars)
- Total assets of Terumo Corporation in fiscal years 2012 to 2017 (in billion Japanese yen)
- Total assets of NuVasive from 2012 to 2018 (in million U.S. dollars)
- Total financial asset ownership for investment funds in the Euro area from 2005 to 2015 (in trillion euros)
- Operating income of the media group Vocento in Spain from 2013 to 2018 (in 1,000 euros)
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Please log in to access our additional functions
Register in seconds and access exclusive features.
Basic Account
|
Instant Access
Premium Account
| ||
|---|---|---|---|
Our services
Click the question mark for further information | Free |
$49 per month* | |
| Basic statistics | |||
| Premium statistics | |||
|
Graph download
| |||
| Download PDF | |||
|
Excel download
| |||
| Register | Purchase now | ||
*Duration: 12 months, billed annually, single license
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.